首页> 外文期刊>Journal of Medicinal Chemistry >Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
【24h】

Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

机译:初始无活性蛋白水解的迭代设计和优化靶向嵌合体(Protacs)识别VZ185作为BRD9和BRD7的效率,快速,选择的von河马 - Lindau(VHL)的双降解探针

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Developing PROTACs to redirect the ubiquitination activity of E3 ligases and potently degrade a target protein within cells can be a lengthy and unpredictable process, and it remains unclear whether any combination of E3 and target might be productive for degradation. We describe a probe-quality degrader for a ligase-target pair deemed unsuitable: the von Hippel-Lindau (VHL) and BRD9, a bromodomain-containing subunit of the SWI/SNF chromatin remodeling complex BAF. VHL-based degraders could be optimized from suboptimal compounds in two rounds by systematically varying conjugation patterns and linkers and monitoring cellular degradation activities, kinetic profiles, and ubiquitination, as well as ternary complex formation thermodynamics. The emerged structure-activity relationships guided the discovery of VZ185, a potent, fast, and selective degrader of BRD9 and of its close homolog BRD7. Our findings qualify a new chemical tool for BRD7/9 knockdown and provide a roadmap for PROTAC development against seemingly incompatible target-ligase combinations.
机译:显影素材以重定向E3连接酶的泛素化活性,并且易于降解细胞内的靶蛋白可以是冗长的和不可预测的方法,并且尚不清楚E3和靶的任何组合是否可以用于降解的任何组合。我们描述了一种探针质量的降解剂,用于连接不合适的旋酶 - 靶对:von Hippel-lindau(VHL)和BRD9,SWI / SNF染色质重塑BAF的含溴酰亚胍氏族亚基。通过系统地改变缀合模式和接头和监测细胞降解活性,动力学谱和泛素,可以在两轮中从次优化合物中从次优化合物中优化基于VHL的降解剂,以及三元复合体形成热力学。出现的结构 - 活动关系引导了BRD9的VZ185,有效,快速和选择性降解的发现和其关闭的同源物BRD7。我们的调查结果有资格获得BRD7 / 9敲低的新化学工具,为Protac开发提供了针对看似不相容的目标连接酶组合的路线图。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2019年第2期|共28页
  • 作者单位

    Univ Dundee Sch Life Sci Div Biol Chem &

    Drug Discovery James Black Ctr Dow St Dundee DD1 5EH Scotland;

    Univ Dundee Sch Life Sci Div Biol Chem &

    Drug Discovery James Black Ctr Dow St Dundee DD1 5EH Scotland;

    Univ Dundee Sch Life Sci Div Biol Chem &

    Drug Discovery James Black Ctr Dow St Dundee DD1 5EH Scotland;

    Univ Dundee Sch Life Sci Div Biol Chem &

    Drug Discovery James Black Ctr Dow St Dundee DD1 5EH Scotland;

    Boehringer Ingelheim RCV GmbH &

    Co KG A-1221 Vienna Austria;

    Boehringer Ingelheim RCV GmbH &

    Co KG A-1221 Vienna Austria;

    Boehringer Ingelheim RCV GmbH &

    Co KG A-1221 Vienna Austria;

    Promega Corp 2800 Woods Hollow Rd Madison WI 53711 USA;

    Promega Corp 2800 Woods Hollow Rd Madison WI 53711 USA;

    Univ Genoa Dipartimento Farm Sez Chim Farmaco &

    Prod Cosmet Viale Benedetto XV 3 I-16132 Genoa Italy;

    Univ Dundee Sch Life Sci Div Biol Chem &

    Drug Discovery James Black Ctr Dow St Dundee DD1 5EH Scotland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号